Related Experiment Video
Updated: Feb 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Treatment of Steroid-Refractory Immune Checkpoint-Related Hepatitis With Ruxolitinib
Vivian V Nguyen1, Malcolm Wells1, Carlos Moctezuma-Velazquez1
1Division of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
The incidence of immune-related hepatitis (IRH) is rising due to increasing use of immune checkpoint inhibitors for the treatment of several malignancies. While most cases respond to corticosteroid therapy, some patients require additional immunosuppressive agents, for which evidence to guide management is still evolving. We present the first documented case of ruxolitinib use as a tertiary agent for IRH following failure of corticosteroids and tocilizumab, suggesting a potential role for Janus kinase inhibitors as a rescue therapy for severe IRH.
The incidence of immune-related hepatitis (IRH) is rising due to increasing use of immune checkpoint inhibitors for the treatment of several malignancies. While most cases respond to corticosteroid therapy, some patients require additional immunosuppressive agents, for which evidence to guide management is still evolving. We present the first documented case of ruxolitinib use as a tertiary agent for IRH following failure of corticosteroids and tocilizumab, suggesting a potential role for Janus kinase inhibitors as a rescue therapy for severe IRH.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Nephrotic Syndrome II : Assessment and Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy